Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Non-Current Assets came in at $141.7 billion in Q1 2026, up 16.05% year-on-year from $122.1 billion in Q1 2025, and down 1.3% quarter-over-quarter from $143.6 billion in Q4 2025.
Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Non-Current Assets across 18 years of filings, most recently posting $141.7 billion for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $141.7 billion, up 16.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $562.4 billion (up 13.7% YoY), and the FY2025 annual result was $143.6 billion, up 15.6% from the prior year.
- Non-Current Assets came in at $141.7 billion for Q1 2026 at Johnson & Johnson, down from $143.6 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $143.6 billion in Q4 2025 to a low of $109.9 billion in Q4 2022.
- The 5-year median for Non-Current Assets is $123.7 billion (2024), against an average of $125.3 billion.
- Across the five-year window, Non-Current Assets dropped 13.64% in 2023 and grew 16.05% in 2026, its largest moves.
- Johnson & Johnson's Non-Current Assets stood at $109.9 billion in 2022, then increased by 3.8% to $114.1 billion in 2023, then grew by 8.9% to $124.2 billion in 2024, then advanced by 15.6% to $143.6 billion in 2025, then fell by 1.3% to $141.7 billion in 2026.
- The last three Non-Current Assets figures came in at $141.7 billion (Q1 2026), $143.6 billion (Q4 2025), and $138.2 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 60.81 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 61.74 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 141.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 102.93 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 59.27 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 141.72 Bn |
| Dec 28, 2025 | 143.59 Bn |
| Sep 28, 2025 | 138.21 Bn |
| Jun 29, 2025 | 138.89 Bn |
| Mar 30, 2025 | 122.12 Bn |
| Dec 29, 2024 | 124.21 Bn |
| Sep 29, 2024 | 125.04 Bn |
| Jun 30, 2024 | 123.27 Bn |
| Mar 31, 2024 | 114.96 Bn |
| Dec 31, 2023 | 114.06 Bn |
| Oct 1, 2023 | 112.36 Bn |
| Jul 2, 2023 | 131.12 Bn |
| Apr 2, 2023 | 131.58 Bn |
| Jan 1, 2023 | 132.08 Bn |
| Oct 2, 2022 | 109.89 Bn |
| Jul 3, 2022 | 113.88 Bn |
| Apr 3, 2022 | 117.93 Bn |
| Jan 2, 2022 | 121.04 Bn |
| Oct 3, 2021 | 119.34 Bn |
| Jul 4, 2021 | 122.67 Bn |